Form 4: Entera Bio Director Receives Equity Compensation

Entera Bio Ltd. Director Yonatan Malca was granted ordinary shares and stock options as compensation for services.

Summary

• Yonatan Malca, a Director of Entera Bio Ltd. (ENTX), reported the acquisition of ordinary shares and stock options.
• On January 1, 2026, Mr. Malca acquired 30,157 ordinary shares, par value NIS 0.0000769 per share, at a transaction price of $0.
• These shares were awarded by the Board of Directors in lieu of cash fees for services rendered as a director for the 2025 fiscal year.
• Additionally, on January 1, 2026, Mr. Malca acquired 33,505 stock options with an exercise price of $1.94.
• These options represent the Board's annual grant to directors and will vest ratably on a quarterly basis over a one-year period commencing January 1, 2026.
• The stock options have an expiration date of January 1, 2036.
• Following these transactions, Mr. Malca beneficially owns 77,416 ordinary shares and 33,505 stock options directly.

Sentiment

Score: 6

Explanation: The filing reports routine director compensation through equity grants, which is a neutral to slightly positive event as it aligns director interests with shareholders. No negative or significantly positive financial performance is indicated.

Positives

• The grant of ordinary shares and stock options aligns the director's interests with those of the shareholders, promoting long-term value creation.
• Equity compensation is a common practice that helps retain experienced board members without immediate cash outflow from the company.

Future Outlook

The granted stock options will vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026, indicating a future schedule for the director's equity accumulation.

Management Comments

• The Board of Directors awarded ordinary shares to the Reporting Person in lieu of cash fees for services rendered as a director for the 2025 fiscal year.
• The options represent the Board's annual grant of options to directors of the Company.

Industry Context

This filing reflects a standard practice within the biotechnology and public company sectors where directors receive a portion of their compensation in the form of equity, such as shares and stock options, to align their incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• Equity compensation for directors, including grants of shares in lieu of cash fees and annual stock option awards, is a widely accepted practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• This approach is consistent with compensation strategies observed in comparable companies, aiming to foster long-term commitment and align director interests with shareholder returns.

Corporate Governance

Related Party Transactions

• The Board of Directors awarded 30,157 ordinary shares to Director Yonatan Malca in lieu of cash fees for services rendered as a director for the 2025 fiscal year.
• The Board of Directors granted 33,505 stock options to Director Yonatan Malca as part of the annual director option grant.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with shareholder interests, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The stock options will vest quarterly over a one-year period starting January 1, 2026.

Key Dates

Keywords

Entera Bio Ltd., ENTX, Form 4, Director Compensation, Stock Options, Equity Grant, Insider Transaction, Corporate Governance